In this interview, Medical News talks to Dr. Bryony HendersonMedical Director for the UK and USA at MedExpressabout his evolving role GLP-1 agonists in obesity care and the future of metabolic health therapies.
Introduce yourself and talk a little about your journey to where you are today.
I am the Medical Director for the UK and US at MedExpresswhere I lead the clinical governance and quality teams. My journey into this role has been defined by a passion for safe, innovative and scalable care.
Prior to joining MedExpress, I built experience in clinical operations and digital health through leadership roles at Kry/Livi and Numan. I have always been committed to being the clinical voice for change, whether through publishing research on health disparities or leading award-winning public health campaigns and speaking to national media.
Today, my focus is on ensuring that as we innovate in the digital space, we remain committed to the highest standards of patient safety.
What do GLP-1 agonists do physiologically and how should patients understand their mechanism of action?
Normally, GLP-1 receptor agonists mimic a natural hormone that our body produces in the gut after eating. These drugs act as a “biological bridge” in three main ways: first, they stimulate the pancreas to release the right amount of insulin. Second, they slow gastric emptying, meaning you feel fuller for longer. and third, perhaps most importantly, they interact with the brain’s reward centers to reduce “food noise” and cravings.
Understanding that this is a hormonal intervention, and not just an appetite suppressant, helps patients see it as a tool to reset their metabolic signals.
Image credit: Alones/Shutterstock.com
Which patient groups are most likely to benefit from GLP-1-based therapies?
These injections are usually prescribed to adults living with obesity who have a body mass index (BMI) of more than 30 or more than 27 if they have other weight-related health problems, such as high blood pressure or prediabetes.
However, looking to 2026, the ‘benefit profile’ is widening, so clinical surveillance remains necessary. Patients benefit most when medication is combined with broader lifestyle restructuring.
Beyond weight loss, are there additional health benefits to using these medications?
Absolutely, and this is one of the most exciting areas of growth for 2026. As clinical evidence accumulates, we see GLP-1s going way beyond the scale. We expect to see these drugs prescribed for a wider range of indications, including osteoarthritis, cardiovascular disease and chronic kidney disease. By 2026, we may see their application in the treatment of sleep apnea and even some neurodegenerative conditions. We’re moving from “weight loss drugs” to “metabolic health stabilizers.”
How sustainable are the results when patients stay on treatments and when they stop?
Sustainability is highly dependent on the care provided. GLP-1s are incredibly effective in inducing weight loss, while in treatment, we know obesity is a chronic condition. Without a strong transition plan, hunger signals can return if treatment is stopped.
This is why, at MedExpress, we focus on increased personalization. by 2026, I expect to see more sophisticated dosing schedules and monitoring tools that will help patients maintain their “off-scale” health improvements long-term, whether they stay on a maintenance dose or transition off it.
How do you manage patient expectations, particularly the perception of GLP-1 agonists as a “quick fix”, and should psychological support be considered with these drugs?
Managing the ‘quick fix’ narrative is a key part of clinical governance. We must be clear: these are medical interventions, not “vanity drugs.” Psychological support is not optional in addition. is often necessary. We need to address the behavioral relationship with food at the same time.
In my view, the most successful treatment models in 2026 will be those that combine medication with behavior change to ensure that the patient’s lifestyle evolves alongside their biology.
What challenges do you see around access, affordability and equity in prescribing GLP-1 agonists? Are there differences in private prescribing models compared to NHS and public health approaches to obesity care?
Image credit: IM Imagery/Shutterstock.com
This is a critical issue. Access through systems such as the NHS remains limited compared to clinical need. The NHS is exploring new models of provision, but uptake still represents only a fraction of the eligible population. This creates a “two-tier” system in which private prescribing offers earlier access.
However, 2026 will be a turning point: as semaglutide loses patent protection in major global markets such as China, Canada and Brazil, and with liraglutide already off patent in the US, the development of generics is expected to reduce costs and improve global share.
Do you think current guidelines and approvals strike the right balance between expanding access to GLP-1 agonists and ensuring appropriate clinical oversight, and what changes, if any, would you make?
Current guidelines offer a strong safety framework, but there is room for further development. As we move toward 2026, I would like to see guidelines that allow for greater “dosage flexibility” and individualized treatment pathways. We must ensure that expanding access, a public health necessity, does not come at the expense of clinical oversight.
My focus is to ensure that, regardless of the delivery model, the patient is always under the care of a clinician monitoring metrics such as blood pressure and heart rate variability.
Do you think GLP-1 agonists are changing the way obesity is perceived as a medical condition versus a lifestyle choice?
Yes, we are witnessing a profound change. They help debunk the “myth of willpower.” By demonstrating how hormonal pathways affect weight, these treatments are redefining obesity as a chronic metabolic disease rather than a lifestyle choice. This change in perception is vital to reducing the stigma that prevented many patients from seeking help in the past.
How do you see GLP-1 agonists fitting into long-term, holistic obesity care over the next decade?
Over the next decade, GLP-1s will be the “anchor” of a much more holistic, data-driven approach. We will see an expansion of options, including new combination therapies and oral formulations such as orforglipron, which will give patients more choice in how they take their medicines. We will see expanded options such as combination therapies and oral formulations such as orforglipron, medication integration with wearable technology, real-time metabolic monitoring and personalized nutritional guidance. We are moving away from ‘one size fits all’ and towards personalized lifelong management of metabolic health.
Where can readers find more information?
About the Researcher
Dr Bryony Henderson joins HeliosX as UK and US Medical Director, bringing extensive experience in clinical operations, governance and digital health from her roles at Kry/Livi and Numan. A recognized clinical voice, she has contributed to award-winning campaigns, published on health inequalities and appeared in major national media outlets. At HeliosX, he leads clinical governance and quality, supporting the delivery of safe, innovative and scalable care.
